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Cisplatin is used frequently as an antineoplastic drug in the 
treatment of many different cancers. However, when used in 
doses over 360mg/m2, ototoxicity may ensue, resulting in loss 
of hearing. Criteria for identifying and quantifying hearing 
loss have been devised. Aim: To describe the features of 
different hearing loss classification systems and to identify 
their implications and use in oncologic patients. Method: 
Hearing loss was classified in 31 patients before and after 
chemotherapy, according to different criteria, assessing 
the sensitivity and specificity of each classification system. 
Results: Hearing loss results were highly variable (ranging 
from 29% to 61%). Only 4 of 31 subjects with post-therapy 
hearing loss were identified by all the methods. A few 
subjects with hearing loss were classified as normal hearing 
in some of the criteria. A normal PTA was found in 18 of 
31 subjects in the post-treatment evaluation. Conclusion: 
None of the criteria assesses the complaints of patients. The 
criteria described in this study were inadequate to identify 
hearing loss following chemotherapy, requiring additional 
information for physicians to better understand the hearing 
losses and their implications for the quality of life of patients. 
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INTRODUCTION
Cisplatin (CDDP) is an antineoplastic drug used 
often in the treatment of various tumors. Side effects 
include: nausea, vomiting, myelosuppression nephrotoxi-
city, central and peripheral neuropathies, and ototoxicity 
(Oliveira1; Rybak et al.2). Ototoxicity may ensue when the 
drug is given at a cumulative dose over 360mg/m2 (Brock 
et al.3; Pedalini et al.4, Simon et al.5, Knoll et al.6). Cisplatin 
ototoxicity is the result of cochlear injury, initially in the 
vascular striae and the outer hair cells of the basal gyrus, 
which result in hearing loss at high frequencies (Rade-
maker et al.7; Rybak et al.8). Continued use of the drug 
may result in hearing loss at low frequencies (Pedalini et 
al.4, Zuur et al.9).
Hearing loss may cause significant loss in the quality 
of life of patients; thus, a concern with ototoxicity should 
be present throughout oncological therapy. Detecting and 
monitoring ototoxicity to initiate preventive measures is 
one of the methods for avoiding hearing loss.
Oncologists are increasingly concerned with drug 
toxicity in oncological therapy, and have created objecti-
ve criteria to measure the specific toxicity for each organ 
during chemotherapy cycles.
Many criteria have been published in the literature, 
with the aim of identifying, describing and even quanti-
fying hearing loss. In this paper we apply four instruments 
that will be described below (Davis and Silverman10; 
Brock et al.3; ASHA-American Speech-language-Hearing 
Association11; NCI12).
In clinical practice, there criteria are difficult to 
apply, since they do not define clearly the degree of he-
aring loss or its impact - patient complaints are not taken 
into account - and do not include all types and grades of 
hearing alterations.
OBJECTIVE
The aim of this study was to assess and identify the 
characteristics of each classification method of hearing loss 
and to adapt them to oncological monitoring.
METHOD
A prospective study was proposed and approved 
by the Research Ethics Committee of the institution in 
which the investigation was to be conducted (acceptance 
number 549/03). All patients were consulted about their 
participation in the study, and signed a free informed 
consent form. Audiological assessments were carried out 
in 31 subjects seen at the Audiology unit; inclusion criteria 
were as follows: cisplatin chemotherapy only; absence of 
ontological complaints; no radiotherapy in the head and 
neck, and pre- and post-therapy audiological assessments.
There were 16 male and 15 female patients. Age 
ranged from 7 to 66 years; the mean age was 28 years.
All subjects in this study underwent full audiological 
testing before, during and after chemotherapy with CDDP; 
however, only conventional pure tone audiometry data 
were computed. A Madsen, Orbiter model version 922 
audiometer was used for measuring air and bone conduc-
tion pure tone auditory thresholds (in dBHL) (Redondo 
et al.13; Yantis14).
Results were tabulated according to classifications 
proposed by various authors and entities. The CTCAE 
(Common Terminology Criteria for Adverse Events12) was 
proposed by the NCI (National Cancer Institute). This ins-
trument aims to describe the adverse events due to chemo-
therapeutic drugs during oncological treatment; numerical 
values (1 to 4) were given to the reactions observed in 
each organ during each chemotherapy cycle (Annex 1).
Brock et al.3 attributed number values (0 to 4) to va-
rious types of hearing loss due to chemotherapy (Annex 2).
The ASHA11 considers ototoxicity as a 20dB threshold 
elevation at a specific frequency, a 10dB threshold eleva-
tion at two consecutive frequencies, or absent responses 
at three consecutive frequencies in post-therapy testing.
Davis and Silverman10 classify the degree of hearing 
loss according to the mean value of thresholds at 500, 1000 
and 2000Hz; normal values - 0 to 20 dB, mild hearing loss 
- 21 to 40 dBHL, moderate hearing loss - 41 to 70 dBHL, 
severe hearing loss - 71 to 90 dBHL, profound hearing 
loss - over 95 dBHL.
A comparison was done taking the 25 dBHL 
threshold as the limit between normal hearing and hearing 
loss to assess the sensitivity and specificity of each crite-
rion, with the aim of analyzing hearing loss according to 
frequency (PPF). Fisher’s exact test was applied to study 
the significance of each method. The GraphPad Prism 
version 2.0 software was used. The significance level was 
< 0.05.
RESULTS
Table 1 shows that, according to NCI12 criteria, 
12 of 31 patients (38%) presented hearing loss at the end 
of therapy. Of these, only one had grade I changes, 10 
had grade II changes, and one had grade III changes. 
According to Brock et al.’s3 criterion, 19 patients (61%) 
presented hearing loss at the end of therapy. Of these, 5 
had grade I changes, 5 had grade II changes, 5 had grade 
III changes, and 4 had grade IV changes. According to 
ASHA11 criteria, 17 subjects (54%) presented hearing loss 
at the end of therapy. Of these, 13 had a 10dB loss in two 
or more frequencies, and 4 had a 15dB loss or more in 
only one frequency. However, 39% of patients had a loss 
over 15dB in two or more consecutive frequencies in at 
least one ear.
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Annex 1. Table of the NCI proposed classification
Common Terminology Criteria for Adverse Events (CTCAE) (2003)
Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events
Version 3.0 DCTD, NCI, NIH, DHHS. March31, 2003 (http:// ctep.cancer.gov) Publishing date, 10 June 2003
Hearing / Ear
Auditory Adverse 
Event
Name 1 2 3 4 5
patient with or 
with no baseline 
audiogram and 
non-monitored 
patients
Hearing:
(monitoring pro-
gram)
Thresholds or 
15 - 25dB de-
crease relative 
to the baseline 
audiogram at two 
or more adjacent 
frequencies in at 
least one ear, or 
subjective change 
in the absence of 
grade 1
Thresholds or 25 
- 90 dB decrease 
in two or more 
adjacent frequen-
cies in at least 
one ear
ADULTS: 
thresholds over 
25 - 90 dB at 3 
adjacent frequen-
cies in at least 
one ear.
 
CHILDREN:
Hearing loss 
sufficient to re-
quire treatment 
including AASI 
(loss > 20dB at 
speech frequen-
cies, bilateral or 
> 30dB unilateral 
and that require 
special phonoau-
diological care)
ADULTS: pro-
found bilateral 
hearing loss
(> 90dB)
 
CHILDREN:
Audiological 
indication for co-
chlear implants, 
requiring special 
phonoaudiologi-
cal care.
-
OBS: pediatric recommendations are similar to those of adults unless otherwise specified. For children and teenagers (< or = 18 years) with 
no pre-treatment baseline audiogram, hearing is considered as below 5dB.
Hearing: patients 
with no baseline 
audiogram and 
not included in a 
monitoring pro-
gram
Hearing: no moni-
toring program
Hearing loss with 
no need to use 
AASI (no effect on 
activities of daily 
life)
Hearing loss with 
no deed to use 
AASI (affecting 
activities of daily 
life)
Profound bilateral 
hearing loss
( > 90dB )
-
Otitis, outer ear 
(non- infectious)
Otitis media
Otitis external 
with erythema or 
dry desquamation
Otitis external 
with desquama-
tion, ear wax or 
effusion, tympa-
nic perforation, 
tympanoplas
ty
Otitis external 
with mastoiditis, 
stenosis or oste-
omyelitis
Necrosis of bone 
or soft tissues
Death
OBS: patients with or with no baseline audiogram, included or not in a monitoring program.
Otitis, middle ear 
(non- infectious)
Otitis media Otitis serous
Otitis serous with 
indication for me-
dical intervention
Otitis with effu-
sion, mastoiditis
Necrosis of canal, 
of bone or soft 
tissues
Death
Tinnitus Tinnitus -
Tinnitus not affec-
ting activities of 
daily life
Tinnitus affecting 
activities of daily 
life
Disability
Loss of function
-
OBS: patients with or with no baseline audiogram, included or not in a monitoring program.
Hearing / Ear 
Others
Hearing / Ear 
Others
mild moderate severe
life risk / loss of 
function
Death
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Davis and Silverman’s10 criteria revealed that 9 sub-
jects (29%) had hearing loss at the end of therapy. The 
identification percentage of hearing loss varied conside-
rably among criteria - from 29% to 61%. We also found 
that 61% had auditory thresholds over 25 dBHL in at least 
one frequency bilaterally.
Statistical analysis consisted of specificity and sen-
sitivity calculations for each criterion; Fisher’s test was 
applied to calculate the p value, as shown on the Table 
below.
Annex 2. Descriptive table of Brock et al.’s proposed classification 
(1991)
Hearing loss Bilateral Grade
< 40dB at all frequencies 0
≥ 40 dB only at 8.000Hz 1
≥ 40 dB starting at 4.000Hz 2
≥ 40 dB starting at 2.000Hz 3
≥ 40 dB starting at 1.000Hz 4
Table 1. Distribution of hearing loss classifications in the study population according to the criteria applied.
Patient BROCK ASHA (2002) NCI SILVERMAN PPF
1 0 0 0 Normal Normal
2 0 0 0 Normal Normal
3 0 0 0 Normal Normal
4 0 0 0 Normal Normal
5 0 0 0 Normal Normal
6 0 0 0 Normal Normal
7 0 0 0 Normal Normal
8 0 1 0 Normal No
9 1 0 0 Normal No
10 0 1 0 Normal 8
11 1 1 2 Normal 8
12 0 0 0 Normal 6
13 0 0 0 Normal 6
14 0 1 0 Normal 250,500
15 1 1 0 Mild 250,8
16 2 0 0 Normal 4,6,8
17 3 0 2 Mild 6,8
18 2 1 2 Normal 4,6,8
19 2 1 2 Normal 4,6,8
20 2 1 2 Normal 4,6,8
21 3 1 0 Normal 4,6,8
22 3 1 2 Normal 4,6,8
23 3 1 2 Normal 4,6,8
24 3 1 2 Normal 4,6,8
25 1 1 0 Mild 2.4.6.8
26 4 1 2 Mild 2,3,4,6,8
27 2 0 0 Mild All
28 1 1 1 Mild All
29 4 1 2 Mild All
30 4 0 0 Moderate All
31 4 1 3 Moderate All
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Table 2 shows Brock’s (1991)3 proposed criteria; 
it had the highest sensitivity. The NCI’s12 and Davis and 
Silverman’s10 criteria were the most specific.
DISCUSSION
The distribution of audiometric thresholds in the 
study sample showed that:
• Only 4 subjects with post-therapy hearing loss 
were identified by all criteria; 7 subjects had no hearing 
loss in any of the criteria applied in this study.
• Thirteen of 18 subjects with normal pure tone 
audiometry (according to Davis and Silverman10) after 
therapy had some degree of hearing loss according to the 
other methods applied in this study.
Brock et al.’s3 criteria demonstrated the highest 
number of significant hearing losses; the ASHA11 criteria 
only revealed whether there was hearing loss or not, but 
provided no quantification.
Auditory losses due to cisplatin ototoxicity are 
generally symmetrical, bilateral, initially affecting high fre-
quencies, followed by middle and low frequencies (Testa 
et al.15; Rademaker et al.7).
Changes were not always detected at the beginning 
by the criteria described above. A major point about these 
criteria is that they do not take the complaints of patients 
into account, which would be extremely important. Addi-
tionally, the impact on a patient’s life may not be propor-
tional to the degree of hearing loss, since this impact de-
pends on factors such as social and professional activities 
and personal aspects. The growing concern on the part of 
oncologists should lead to careful prevention of hearing 
loss, comprising periodic testing and close monitoring of 
hearing losses, not waiting for patients to complain before 
becoming concerned with hearing; this means preventing 
the onset of hearing loss and not only rehabilitation when 
hearing cannot be recovered any longer.
A relevant point was that NCI12 criteria were not 
sufficiently specific for monitoring auditory function; 
it does not define clearly which frequencies should be 
investigated.
Audiologically, there are monitoring proposals using 
conventional frequencies (Testa et al.15, Kushner et al.16, 
Marshall et al.17, Toral-Martinnon et al.18), monitoring pro-
posals using transient otoacoustic emissions (Liberman19) 
or distortion products (Biro et al.20; Hyppolito et al.21), 
and monitoring proposals using high frequencies (over 
8000 Hz) (Garcia22), which may be first affects by ototoxic 
drugs. In this case, patients with hearing loss normally 
do not complain and not always perceive loss of hearing 
(Liberman23). Dhooge et al.,24 however, found sympto-
matic ototoxicity in 20% of cases - auditory complaints 
in 16 children treated with cisplatin and/or carboplatin. 
Monitoring with conventional frequencies (500 to 8000 
Hz) shows that hearing loss leads to difficulties in diffe-
rent situations; patients may complain only of tinnitus or 
difficulties to understand speech in noisy environments, or 
may present hearing loss at speech frequencies, no longer 
being able to follow a conversation. Still in the criterion 
for patients with auditory changes in pre-therapy testing, 
these subjects may be classified as not having post-therapy 
auditory changes; but therapy will have caused elevated 
audiometric thresholds, which are not taken into account 
in the final criterion.
A further discrepancy is the grade II in this criterion. 
This grade includes patients that had a 25 to 90 dB eleva-
tion of the auditory threshold. A 25 dB threshold elevation 
may go unnoticed or may cause minimal difficulty; it may 
even be classified as mild hearing loss (Davis and Silver-
man10). On the other hand, a 90 dB elevation suggests that 
subjects will probably not follow a conversation without 
using hearing aids, since voice during a conversation is 
issued at around 60 dBHL. Furthermore, hearing loss here 
is classified as severe, which brings significant restrictions 
on social life. Classifying these two extremes of threshold 
elevations in the same grade does not take into account 
the significant differences, complaints and limitations.
Table 2. Sensitivity and Specificity, with their respective confidence intervals (CI), for each criterion.
Criteria    Hearing loss  
  YES NO  
 Brock Hearing loss
YES 18 1 Specificity: 81.8%
NO 4 8 Sensitivity: 88.9%
 ASHA (2002) Hearing loss
YES 16 1 Specificity: 88.9%
NO 6 8 Sensitivity: 72.7%
 NCI Hearing loss
YES 12 0 Specificity: 100%
NO 10 9 Sensitivity: 54.5%
 SILVERMAN Hearing loss
YES 9 0 Specificity: 100%
NO 13 9 Sensitivity: 40.9%
639
Brazilian Journal of otorhinolaryngology 75 (5) SeptemBer/octoBer 2009
http://www.bjorl.org  /  e-mail: revista@aborlccf.org.br
The 40 dB reference in Brock et al.’s10 proposed 
criteria is debatable. A 40 dB loss characterizes mild hea-
ring loss, with serious implications for the perception of 
Portuguese consonants (Russo and Behlau25), especially 
in children, for which this classification was proposed. 
This author does not take into account changes above 
40 dB that may occur at single frequencies, as well as 
not considering small auditory alterations that may occur 
before the auditory threshold reaches 40 dB. Intensity is 
an important factor in hearing loss; it is also important in 
rehabilitation with hearing aids, and may be a limiting 
factor in choosing and using an appropriate aid.
The ASHA11 criteria do not account for affected 
frequencies; from an audiological perspective this has 
implications for the follow-up of oncological therapy. A 
10 dB threshold increase at 6000 and 8000 Hz may not 
result in minimal hearing loss, depending on age, while a 
20 dB decrease at 1000 and 2000 Hz in a patient with a 30 
dB pre-treatment threshold causes moderate hearing loss 
and may result in significant communication difficulties. 
Thus, the affected frequency should be taken into account.
Davis and Silverman10 proposed criteria is not in-
dicated for oncological patients, since it classifies hearing 
loss only at 500, 1000 and 2000 Hz thresholds, which are 
not those commonly involved in ototoxicity.1,26-27 This is 
a problem, because when ototoxic drug induced hearing 
loss affects these frequencies, loss is already significant and 
patients present major complaints; it is thus inadequate 
for monitoring patients at risk of hearing loss - when this 
criterion detects loss, it is already rather advanced.
The same subject with hearing loss was not always 
classified by all of the criteria above; thus, the sensitivity 
and/or specificity of each criterion needs to be known, as 
small changes in hearing are not always detected by these 
instruments. Important hearing losses are easily detected 
by any of these tools; however, a classification instrument 
should detect small changes so that oncologists and speech 
therapists may carefully monitor the hearing function of 
these patients, to avoid major loss of function.
The classification of hearing loss in audiological 
evaluations during oncological therapy aims firstly to iden-
tify ototoxic effects, especially at high frequencies. This 
makes it possible for physicians to be alert and change 
therapy protocol measures. Secondly, the classification 
should indicate at which point patients will suffer the so-
cial, educational and professional implications of hearing 
loss. Impact differs in adults and children, both in terms 
of the degree of hearing loss and the affected frequencies. 
A classification should be able to show the progression 
of hearing loss.
Knight et al.28 monitored ototoxicity in 67 children 
with osteosarcoma, neuroblastoma and medulloblastoma, 
all of which were treated with cisplatin. These authors 
compared the Brock et al.,3 ASHA,11 and NCI12 criteria, and 
also found it difficult to adequately describe hearing losses. 
These authors believe that those criteria underestimate 
hearing loss resulting from oncological therapy; the result 
of this is that language development, learning and social/
emotional function may be compromised in these children. 
These authors also found that hearing loss may lead to 
low self-esteem, behavioral disorders, loss of energy and 
stress, compared to normal hearing children; these factors 
are not included in any of these classification systems.
Liberman29 studied patients with cancer treated 
during childhood with cisplatin, and found a higher occur-
rence of auditory complaints when hearing loss affected 
the 4000Hz frequency.
Marini et al.30 analyzed the predictive power, sensi-
tivity and specificity of auditory complaints in 795 patients 
and found that the sensitivity was high (80.9%) and the 
specificity was 60.4%. Audiometric test results should also 
be available; although more subjective, these results are 
less costly than new technologies.
Teles et al.31 compared data such as frequency, 
proportion, agreement and consistency of responses in 
workers exposed to occupational noise; significant chan-
ges were noted in the audibility threshold (MSL). These 
authors applied three Brazilian criteria and one interna-
tional criterion to analyze threshold changes and found 
that these criteria in themselves were inadequate, given 
their subjective nature; prevention would be necessary 
not only in subjects presenting MSL but in all subjects in 
an auditory preservation program.
Gupta et al.32 found a small incidence of hearing 
loss in children undergoing cisplatin chemotherapy by 
continuous infusion; these authors used Brock’s criterion 
and concluded that continuous drug administration is as-
sociated with a lower incidence of ototoxicity. However, 
we believe that this criterion underestimates important 
losses in this population because it takes into account 
only losses over 40 dB.
According to the literature we cited, changes in 
hearing were not always detected at the beginning in onco-
logical patients by the criteria described in this study. The 
main criticism of these criteria is that they do not include 
patient complaints, essential for understanding the impact 
of hearing loss on patient’s lives, which are not always 
proportional do the degree of loss, but depend on factors 
such as personal, social and professional activities. The 
growing concern of oncologists should lead to preventive 
care to avoid hearing loss; this includes periodic testing 
and close monitoring of auditory changes before patients 
complain to avoid hearing loss rather than just rehabilita-
tion when reversion is no longer possible.
Each classification tool should be assessed accor-
ding to its purpose. In the case of hearing loss associated 
with oncological therapy, we believe it is relevant not 
only to identify, classify and quantify auditory losses, but 
640
Brazilian Journal of otorhinolaryngology 75 (5) SeptemBer/octoBer 2009
http://www.bjorl.org  /  e-mail: revista@aborlccf.org.br
also to investigate eventual complains and the impact that 
hearing loss may cause on the quality of life of patients. 
It is impossible to define the degree of hearing loss that 
results in complaints and difficulties for patients using 
only the criteria mentioned above for classifying auditory 
losses. Thus, identifying and validating the complaints of 
patients is just as important as audiological evaluations 
and classification of losses according to charts.
It is extremely important to note that the criterion 
used for classifying hearing losses in oncological patients 
should be able to identify the beginning of loss, thus avoi-
ding unnecessary adverse effects and preventing auditory 
losses due to oncological therapy.
CONCLUSION
We found that Davis and Silverman’s10 criteria sho-
wed hearing loss in 29% of subjects at the end of treatment; 
the NCI12 criteria showed hearing loss in 38% of patients; 
the ASHA11 criteria showed hearing loss in 54%; and Brock 
et al.’s3 criteria showed hearing loss in 61% of patients 
at the end of oncological therapy. Thus, Brock’s (1991)3 
proposed criteria was the most sensitive, and the NCI’s12 
and Davis and Silverman’s10 criteria were the most specific.
However, all of these criteria underestimated the 
description of identified auditory alterations; additional 
information was required to help physicians to understand 
the true implications of hearing loss in each case.
A common code is needed between audiologists 
and oncologists to increase our understanding and improve 
the therapy of these patients; not only should the grade 
and type of hearing loss be described, but also the impact 
on the lives of patients.
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